CAL
JANX icon

Capital Advisors Ltd’s Janux Therapeutics JANX Stock Holding History

Capital Advisors Ltd’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+8
New +$116 ﹤0.01% 1475
2022
Q4 		– Sell
-90
Closed -$1K – 1415
2022
Q3 		$1K Buy
+90
New +$1.2K ﹤0.01% 1042

Other funds holding JANX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
APW
Aventura Private Wealth Aventura, Florida $326M AUM 34.36% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return

Capital Advisors Ltd's JANX Position: Q2 2026 in Review

Capital Advisors Ltd opened a new position in Janux Therapeutics (JANX) in Q2 2026: 8 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1475 among its holdings. This is a return to the name: Capital Advisors Ltd previously reported a position in JANX as recently as Q3 2022.

Capital Advisors Ltd first reported a position in JANX in Q3 2022 and has held it in 2 quarters since. The position peaked at $1K in Q3 2022. 12 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Capital Advisors Ltd held 8 shares of Janux Therapeutics worth $0 as of Q2 2026.
  • Janux Therapeutics was a new Capital Advisors Ltd position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1475 holding.
  • Capital Advisors Ltd first reported a position in Janux Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • Capital Advisors Ltd's Janux Therapeutics position peaked at $1K in Q3 2022.
  • 12 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.